Satish Jindal

Satish Jindal serves as CEO of Allied-Bristol Life Sciences, LLC (ABLS) companies. Prior to ABLS, Satish served as a vice president, Bristol-Myers Squibb (BMS), and managing director of Biocon-Bristol-Myers Squibb Research Center (BBRC) in Bangalore, India. BBRC is an affiliate of BMS with ~575 R&D people with expertise in the discovery and early development of drug candidates. During his tenure at BMS, he partnered with Allied Minds and BMS teams to create the unique innovator model, ABLS. He has extensive experience in forming and building biotechnology companies, including Vedantra Inc., an immunotherapy company that he co-founded based on intellectual property from the Koch Institute at the Massachusetts Institute of Technology (MIT); Verastem Inc., a NASDAQ-listed cancer stem cell company that he co-founded with researchers from the Whitehead Institute, the Broad Institute, and MIT; and NeoGenesis Inc., a drug discovery company that was acquired by Schering-Plough in 2005. He was a Vice president and Site Head at Schering-Plough Research Institute in Cambridge, Massachusetts from 2005-2008 and also worked in Business Development at UCB Pharma in the UK. He did his postdoctoral work at Whitehead Institute for Biomedical Research at MIT, Cambridge, MA, and at McMaster University, Hamilton, Ontario, Canada, and obtained his Ph.D. in Biochemistry from Punjab University, India.